Journal of Vascular and Interventional Radiology最新文献

{"title":"First-in-Human Evaluation of a New Resorbable Microspherical Embolic Agent for Genicular Artery Embolization to Treat Pain Secondary to Knee Osteroarthritis.","authors":"Mark W Little, Sankalp Agarwal, Ibrohim M Khikmatovich, Joan McCabe, Masum Pandey, Andrew L Lewis, Liam Farrissey, Sherzod A Iskhakov","doi":"10.1016/j.jvir.2025.07.010","DOIUrl":"10.1016/j.jvir.2025.07.010","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the safety and effectiveness of genicular artery embolization (GAE) using an resorbable microspherical embolic agent to treat pain secondary to knee osteoarthritis (KOA).</p><p><strong>Materials and methods: </strong>This prospective, single-arm, unblinded, first-in-human study was performed in 15 patients (12 women; mean age, 62.8 years). GAE was performed with 200-μm (SD ± 75) resorbable alginate microspheres (SakuraBead; CrannMed, Galway, Ireland). The primary endpoint was safety, with effectiveness evaluated as a secondary endpoint using the visual analog scale (VAS) pain score and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline, 1 month, 3 months, and 6 months. Adverse events were recorded at all timepoints.</p><p><strong>Results: </strong>GAE was technically successful in all patients. There were 6 adverse events recorded in 6 different patients; all were minor and self-limited (Grade 1). The percentage reduction in VAS, WOMAC total, and WOMAC pain scores was calculated for individual patients. This showed that there was a statistically significant reduction (P < .001) in the mean VAS score of 76%, 77%, and 63% at 1, 3, and 6 months, respectively. There was a 78% reduction in WOMAC total score at both 1 and 3 months and a 76% reduction at 6 months (P < .01); this was accompanied by a reduction in WOMAC pain score of 78%, 81%, and 78% at 1, 3, and 6 months, respectively (P < .01).</p><p><strong>Conclusions: </strong>In this limited pilot study, GAE using alginate resorbable microspheres was safe and produced significant improvement in pain and function in patients with KOA maintained to 6-month follow-up.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Aldosteronoma Resolution Score as a Predictive Metric for Outcomes after Radiofrequency Ablation for Primary Aldosteronism.","authors":"Marwan Moussa, Omar Hamam, Ahmad Maaly, Mohammed Elkholy, Mohamed Farghaly, Godwin Abiola, Salomao Faintuch, Barry Sacks, Anand Vaidya, Muneeb Ahmed, Ammar Sarwar","doi":"10.1016/j.jvir.2025.07.011","DOIUrl":"10.1016/j.jvir.2025.07.011","url":null,"abstract":"<p><strong>Purpose: </strong>To validate the Aldosteronoma Resolution Score (ARS), a validated metric for prognostication of complete clinical response after adrenalectomy, as a prognosticator for outcomes after radiofrequency (RF) ablation for treatment of primary aldosteronism (PA).</p><p><strong>Material and methods: </strong>After institutional review board (IRB) approval, patients treated with RF ablation for a unilateral aldosteronoma between 2007 and 2023 were retrospectively reviewed. Clinical and biochemical data were collected, including preprocedural and postprocedural potassium, aldosterone, and plasma renin activity levels; blood pressure (BP); and number and doses of antihypertensives. Analysis included descriptive analysis and area under the curve (AUC)-receiver operator characteristic tests assessing the relation between ARS and outcomes after RF ablation. ARSs were defined as \"high likelihood of clinical response\" (4-5), \"medium likelihood of clinical response\" (2-3), and \"low likelihood of clinical response\" (0-1). Outcome definitions were complete clinical response (BP < 140/90 mm Hg, without antihypertensives), partial clinical response (BP < 140/90 mm Hg, requiring less antihypertensives before RF ablation), and absent clinical response (BP < 140/90 mm Hg, requiring unchanged antihypertensives before RF ablation). ARS correlation with post-RF ablation biochemical data was performed as an exploratory endpoint.</p><p><strong>Results: </strong>In 59 patients (71% men) with a mean age of 54.4 years (SD ± 10.3), 15% achieved complete clinical response and 8% had high ARS, 46% had partial response and 46% had medium ARS score, and 39% had absent clinical response and 46% had low ARS score. The AUC for predicting complete clinical response was 0.891 (95% CI, 0.795-0.987; P < .001).</p><p><strong>Conclusions: </strong>Preliminary evidence demonstrated that ARS can be used for predicting clinical outcomes in PA after RF ablation.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foam Fortification: Effect of Perfluorocarbon Gases on the Stability of Sclerosing Agent Foams.","authors":"Henry Ruhl, Felipe M Berg, Amir A Rahnemai-Azar, Salim Abboud, Agata A Exner","doi":"10.1016/j.jvir.2025.07.009","DOIUrl":"10.1016/j.jvir.2025.07.009","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of incorporating perfluorocarbons (PFCs), specifically octafluoropropane (C₃F₈) and perfluorobutane (C₄F₁₀), on the stability of sodium tetradecyl sulfate (STS)-based foams.</p><p><strong>Materials and methods: </strong>Tessari method was employed to generate foams. C₃F₈ and C₄F₁₀ were compared with room air due to their known characteristic as gas vesicle stabilizers. Each trial set encompassed ratios of 4, 3, 2, 1.5:1 mL of gas-to-STS. Foam decay (1 - percent foam remaining in syringe) was monitored using a 4K camera over 1 hour, followed by hourly snapshots for 3 hours. All trials were repeated in triplicate. Statistical analysis was carried out via 1-way analysis of variance and, where appropriate, Student t-test.</p><p><strong>Results: </strong>PFC-stabilized foams exhibited greater stability than room air-stabilized foams, with C₄F₁₀ demonstrating the highest stability. Room air-stabilized foams fully decayed within 30 minutes, whereas PFCs maintained over 70% foam volume for up to 45 minutes. Notably, a significant decrease in foam stability was observed in the 4:1 PFC:STS of C₃F₈ between 60 and 180 minutes, a decline that was not observed in C₄F₁₀ foams (P < .001). Although decreasing the room air:STS ratio diminished foam stability for room air, it enhanced stability in PFC-stabilized foams. Specifically, the 4:1 PFC:STS ratio sustained approximately 15% more foam than the 1.5:1 gas:STS ratio over 180 minutes, aside from the substantial decrease in C₃F₈ foams. These findings suggest that PFCs improve the stability of sclerosing foams.</p><p><strong>Conclusions: </strong>C₃F₈ and C₄F₁₀ showed greater stability with STS compared with room air, and C₄F₁₀ exhibited better stability over time than C₃F₈.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing Tilt and Retrieval Challenges with Inferior Vena Cava Filters: Comparison of Original and Antitilting Models of the ALN Filter","authors":"Sylvain Grange MD, PhD ,&nbsp;Pierre Cixous MD ,&nbsp;Géraldine Poenou MD, PhD ,&nbsp;Geoffroy Guillaubey MD ,&nbsp;Elie Ayoub MD ,&nbsp;Claire Boutet MD, PhD, Pr ,&nbsp;Laurent Bertoletti MD, PhD, Pr ,&nbsp;Rémi Grange MD","doi":"10.1016/j.jvir.2025.07.005","DOIUrl":"10.1016/j.jvir.2025.07.005","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the tilt of the classical ALN (ALN Implants Chirurgicaux, Bormes-Les-Mimosas, France) inferior vena cava filter (IVCF) with that of the new optional antitilting inferior vena cava filter (OATF) in a single-center retrospective study.</div></div><div><h3>Materials and Methods</h3><div>This retrospective study analyzed fluoroscopic images from 539 patients who received an IVCF between April 2012 and March 2023. The primary outcome was the frontal view tilt angle of the IVCF within the inferior vena cava at insertion between the ALN classical filter (ACF) and the new OATF. Secondary outcomes included a comparison of tilt between these 2 filters at retrieval and a correlation between tilt and fluoroscopy time. Imaging and clinical data were collected from hospital databases, and statistical analysis was conducted using regression models.</div></div><div><h3>Results</h3><div>At placement, in the frontal view, median tilt was significantly lower in the OATF group (5° [2°–10°]) than in the ACF group (10° [6°°–15°]) (<em>P</em> &lt; .01). At retrieval, the median frontal view tilt was significantly lower in the OATF group (3.5° [1°–10°]) than in the ACF group (11° [5°–16.5°]) (<em>P</em> &lt; .01). Median lateral view tilt at retrieval was also significantly lower in the OATF group (3° [1°–6.5°]) than in the ACF group (8° [4°–13°]) (<em>P</em> &lt; .001). At retrieval, frontal view tilt was correlated with fluoroscopy time (Spearman correlation coefficient, 0.165; n = 184) (<em>P</em> = .033).</div></div><div><h3>Conclusions</h3><div>The OATF is associated with reduced tilt compared with the classical model.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"36 10","pages":"Pages 1605-1612"},"PeriodicalIF":2.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144651084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improved Outcomes from Prolonged Percutaneous Biliary Drainage in Pediatric Patients with Biliary Stenosis after Liver Transplantation.","authors":"Christin Fürnstahl, Elif Can, Simone Hammer, Michael Doppler, Niklas Verloh, Birgit Knoppke, Dirk Grothues, Michael Melter, Stefan M Brunner, Hans Jürgen Schlitt, Wibke Uller","doi":"10.1016/j.jvir.2025.07.006","DOIUrl":"10.1016/j.jvir.2025.07.006","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate patency rates, outcomes of percutaneous transhepatic biliary drainage (PTBD), and predictors of stenosis recurrence.</p><p><strong>Materials and methods: </strong>A retrospective analysis of 47 PTBDs in 40 pediatric patients after pLT (2009-2019) was performed. Six patients underwent repeated PTBD for recurrent biliary strictures. Kaplan-Meier, log-rank, and Cox regression analyses evaluated patency and influencing factors. Management followed institutional protocols with drain upsizing every 6-8 weeks. The median age and weight were 1.8 years (interquartile range [IQR], 0.8-8.2) and 9.9 kg (IQR, 7.5-19.6), respectively.</p><p><strong>Results: </strong>The median interval from pLT to PTBD was 122 days (IQR, 55-626). The primary patency rates were 89.4% at 1 year and 86.3% at 5 years, with 15% restenosis after a median of 8.5 months. Repeat PTBD achieved patency rates of 100% at 1 year and 83.3% at 5 years (exploratory). Patency declined with dwell times of <5 months (P = .015), biliary leaks limited to the period before or during PTBD (post-PTBD leaks showed no association), hepaticojejunostomy revision, complex portal-vein reconstruction, and low- to moderate-grade hepatic artery stenosis. Longer dwell time reduced recurrence risk (hazard ratio, 0.52; 95% confidence interval, 0.30-0.89). Elevated alkaline phosphatase, bilirubin, gamma-glutamyl transferase, and aspartate aminotransferase levels were predictive of recurrence (P < .05).</p><p><strong>Conclusions: </strong>PTBD ≥5 months improved biliary patency and reduced restenosis risk. Shorter durations increased recurrence risk. Outcomes depended on PTBD duration, vascular status, bile leaks, and surgical complexity. Laboratory changes during and after therapy may have indicated recurrent stenosis.</p>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response to Bland Embolization and Targeted Therapy of an Unresectable, Hemorrhagic, Recurrent Papillary Thyroid Carcinoma.","authors":"Isa Cam, Damla Köksalan, Almotasem Shatat, Berrin Cetinarslan, Zeynep Canturk, Ercüment Çiftçi","doi":"10.1016/j.jvir.2025.07.008","DOIUrl":"10.1016/j.jvir.2025.07.008","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Marrow Concentrate Intra-Articular Injections for Knee Osteoarthritis: Updated 5-Year Clinical Outcomes in 71 Patients","authors":"Alain Silvestre MD ,&nbsp;Pierre-Francois Lintingre MD ,&nbsp;Nicolas Bouguennec MD ,&nbsp;Benjamin Dallaudiere MD, PhD","doi":"10.1016/j.jvir.2025.06.026","DOIUrl":"10.1016/j.jvir.2025.06.026","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"36 10","pages":"Pages 1621-1623"},"PeriodicalIF":2.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Effectiveness of Image-Guided Therapies for Giant Hepatic Hemangiomas: A Systematic Review and Meta-Analysis of 2,617 Patients","authors":"Ahmet Günkan MD ,&nbsp;Alperen Elek MS ,&nbsp;Victor Arthur Ohannesian MS ,&nbsp;Lucas Lima Mendes MS ,&nbsp;Umur Anil Pehlivan MD ,&nbsp;Mohamed E.M. Fouad MD ,&nbsp;Murtaja Satea Shafeea MS ,&nbsp;Romaric Loffroy MD, PhD ,&nbsp;Jack Hannallah MD, MPH, MBA ,&nbsp;Gregory Woodhead MD, PhD ,&nbsp;Shamar Young MD","doi":"10.1016/j.jvir.2025.06.025","DOIUrl":"10.1016/j.jvir.2025.06.025","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the safety and effectiveness of image-guided therapies—including transarterial chemoembolization (TACE), radiofrequency (RF) ablation, microwave ablation, and percutaneous sclerotherapy—for the treatment of giant hepatic hemangiomas (GHHs).</div></div><div><h3>Materials and Methods</h3><div>A comprehensive search was performed across PubMed, Scopus, and Web of Science, including studies with ≥5 patients that reported image-guided treatment of GHHs. Primary outcomes included technical success, adverse events (AEs; classified according to the Society of Interventional Radiology [SIR] system), clinical success (symptom relief without additional intervention), and radiologic success (≥50% size reduction and/or lack of enhancement on follow-up imaging). A subgroup analysis was performed for GHHs of ≥10 cm. Outcomes were analyzed using a random-effect meta-analysis.</div></div><div><h3>Results</h3><div>Twenty-eight studies (2,617 patients; 32.5% men; mean age, 46.1 years [SD ± 3.2]) with 2,996 GHHs, ranging from 4 to 30 cm, were included. Of these, 22 were noncomparative, and 6 compared either 2 image-guided therapies or surgery, reporting outcomes for TACE (n = 13), RF ablation (n = 7), microwave ablation (n = 6), and percutaneous sclerotherapy (n = 4). The pooled technical success rate was 99.9%. Grade 2–4 AEs occurred in 1.64%, with TACE having the lowest rate (0.2%) and RF ablation the highest (2.1%). Clinical success at final follow-up was 99.9%, while radiological success was 85.7%. Grade 2–4 AEs were significantly higher in the subanalysis of GHHs of ≥10 cm (10.6%; <em>P</em> &lt; .001), despite similar technical success and radiological and clinical outcomes.</div></div><div><h3>Conclusions</h3><div>Image-guided therapies are safe and effective for GHHs, achieving high technical, clinical, and radiological success with minimal Grade 2–4 AEs. However, for GHHs ≥10 cm, AE rates were higher.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"36 10","pages":"Pages 1502-1512.e18"},"PeriodicalIF":2.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thermal Ablation Modalities That Best Compete with Partial Nephrectomy for T1A and T1B Renal Cell Carcinoma: A Network Meta-Analysis","authors":"Mahmoud Shaaban Abdelgalil MD ,&nbsp;Alina Ghazou MBBCh ,&nbsp;Mohamed A. Aldemerdash MD ,&nbsp;Mohamed Abdelaal Nasser MBBCh ,&nbsp;Hajer Bassem MBBCh ,&nbsp;Ahmad Abdelrazek MD ,&nbsp;Asmaa Elganady MBBCh ,&nbsp;Mohamed Mansour MBBCh ,&nbsp;Ahmed K. Awad MD ,&nbsp;Omar Saeed MBBCh ,&nbsp;Ayman K. Awad MBBCh ,&nbsp;Mohamed Abd-ElGawad MBBCh","doi":"10.1016/j.jvir.2025.05.032","DOIUrl":"10.1016/j.jvir.2025.05.032","url":null,"abstract":"<div><h3>Purpose</h3><div>To address the lack of consensus on the ranking of thermal ablation (TA) for treating T1A and T1B renal cell carcinoma (RCC), a network meta-analysis was conducted to compare the efficacy and safety of different TA modalities for managing early-stage RCC.</div></div><div><h3>Methods</h3><div>The Cochrane Library, PubMed, Scopus, and Web of Science were systematically searched for studies comparing percutaneous and laparoscopic radiofrequency ablation (RFA), cryoablation (CRA), and microwave ablation (MWA) with open, laparoscopic, and robotic partial nephrectomy (PN) for T1A and T1B RCC. Primary outcomes were recurrence-free survival (RFS), local recurrence, and postprocedural adverse events. Secondary outcomes included overall survival, cancer-specific mortality, changes in estimated glomerular filtration rate, hospital stay length, major adverse events, operation time, and systemic recurrence.</div></div><div><h3>Results</h3><div>Thirty-two studies were included, comprising 8,568 patients in T1A studies and 1,019 in T1B studies. For T1A tumors, no significant differences in 5-year RFS were observed between open PN and percutaneous RFA (<em>P</em> = .655), percutaneous CRA (<em>P</em> = .369), laparoscopic RFA (<em>P</em> = 1.000), or laparoscopic CRA (<em>P</em> = .547). However, percutaneous MWA reduced local recurrence (<em>P</em> = .033) and had lower postprocedural adverse events compared with PN (<em>P</em> = .029). For T1B tumors, no significant differences in 5-year RFS, local recurrence, or postprocedural adverse events were observed between open PN and percutaneous RFA or percutaneous CRA.</div></div><div><h3>Conclusion</h3><div>Although data gaps exist, percutaneous TA demonstrated outcomes comparable with surgery for both T1A and T1B renal tumors. For T1A tumors, percutaneous MWA may be highly effective. For T1B tumors, the similar outcomes across percutaneous approaches support tailoring treatment based on patient factors and operator expertise.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"36 10","pages":"Pages 1475-1491.e53"},"PeriodicalIF":2.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anomalous Origins of the Prostatic Artery from the Inferior Mesenteric Artery Identified during Prostatic Artery Embolization","authors":"Megan Worthington MS ,&nbsp;Timothy Carlon MD, MBA ,&nbsp;David Bamshad MD ,&nbsp;Ricki Gottlieb MD ,&nbsp;Aaron Fischman MD","doi":"10.1016/j.jvir.2025.06.024","DOIUrl":"10.1016/j.jvir.2025.06.024","url":null,"abstract":"","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"36 10","pages":"Pages 1626-1628"},"PeriodicalIF":2.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144568054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}